fda glp 1 New GLP-1 Pill Foundayo (Orforglipron) Gets Approval for Obesity News Brief: FDA Seeks Removal

FDA approval requires rigorous testing for safety, dosing consistency, and effectiveness

Operating in this environment is SureNano Science Ltd

Key takeaways include: Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026

doi: 10.1007/s00125-009-1562-x

Their appeal lies in their holistic nature

The protective actions of GLP-1RAs in the heart involve GLP-1R, kinases (protein kinase C epsilon (PKC), PKA, Akt, adenosine 5 -monophosphate-activated protein kinase (AMPK), PI3K, extracellular signal-regulated kinase 1 and 2 (ERK1/2), mammalian target of rapamycin (mTOR), glycogen synthase kinase-3 (GSK-3), protein kinase G (PKG), mitogen activated protein kinase 1 and 2 (MEK1/2), and mitogen activated protein kinase 3 (MKK3)), enzymes (heme oxygenase 1 (HO-1) and endothelial nitric oxide synthase (eNOS)), transcription factors (signal transducer and activator of transcription 3 (STAT3), cAMP-response element binding protein (CREB), nuclear factor (erythroid-derived 2)-like 2 (Nrf2), and forkhead box protein O3 (FoxO3)), adenosine triphosphate-sensitive potassium channel (KATP) channel opening, and mitochondrial permeability transition pore closure [49]